NZ538391A - Quinoline derivatives and their use as mycobacterial inhibitors - Google Patents
Quinoline derivatives and their use as mycobacterial inhibitorsInfo
- Publication number
- NZ538391A NZ538391A NZ538391A NZ53839103A NZ538391A NZ 538391 A NZ538391 A NZ 538391A NZ 538391 A NZ538391 A NZ 538391A NZ 53839103 A NZ53839103 A NZ 53839103A NZ 538391 A NZ538391 A NZ 538391A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- compound according
- alkyl
- phenyl
- formula
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title claims description 4
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title description 6
- 239000003112 inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 199
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 239000002253 acid Substances 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 15
- 125000000815 N-oxide group Chemical group 0.000 claims abstract 2
- -1 cyano, hydroxy Chemical group 0.000 claims description 73
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 125000005843 halogen group Chemical group 0.000 claims description 44
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 41
- 150000003254 radicals Chemical class 0.000 claims description 41
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000004432 carbon atom Chemical group C* 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 21
- 201000008827 tuberculosis Diseases 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 19
- 230000008018 melting Effects 0.000 claims description 19
- 238000002844 melting Methods 0.000 claims description 19
- 125000004122 cyclic group Chemical group 0.000 claims description 17
- 125000004414 alkyl thio group Chemical group 0.000 claims description 15
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000002883 imidazolyl group Chemical group 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 7
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 7
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 241000187480 Mycobacterium smegmatis Species 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 4
- 125000000597 dioxinyl group Chemical group 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002346 iodo group Chemical group I* 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 71
- 238000002360 preparation method Methods 0.000 abstract description 35
- 238000000034 method Methods 0.000 abstract description 15
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract description 7
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000003937 drug carrier Substances 0.000 abstract description 5
- 241000186367 Mycobacterium avium Species 0.000 abstract description 4
- 241000186366 Mycobacterium bovis Species 0.000 abstract description 4
- 241000187492 Mycobacterium marinum Species 0.000 abstract description 4
- 230000001717 pathogenic effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- 239000000243 solution Substances 0.000 description 46
- 239000002904 solvent Substances 0.000 description 40
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- 239000007787 solid Substances 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- 239000003480 eluent Substances 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000002244 precipitate Substances 0.000 description 19
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- 239000002585 base Substances 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 229940126214 compound 3 Drugs 0.000 description 13
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 13
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 10
- 239000005457 ice water Substances 0.000 description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 8
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 8
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 6
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 6
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 6
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940126543 compound 14 Drugs 0.000 description 6
- 229940125758 compound 15 Drugs 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 150000003335 secondary amines Chemical class 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 5
- 150000003248 quinolines Chemical class 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 3
- QMNXJNURJISYMS-UHFFFAOYSA-N 3-(dimethylamino)-1-phenylpropan-1-one Chemical compound CN(C)CCC(=O)C1=CC=CC=C1 QMNXJNURJISYMS-UHFFFAOYSA-N 0.000 description 3
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical class O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 3
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 3
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- CXDXSNWZXJVDMC-UHFFFAOYSA-N 3-(dimethylamino)-1-naphthalen-1-ylpropan-1-one Chemical compound C1=CC=C2C(C(=O)CCN(C)C)=CC=CC2=C1 CXDXSNWZXJVDMC-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 2
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000013100 final test Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical class C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NZQUUDNNULYMRT-UHFFFAOYSA-N 1-(2,5-difluorophenyl)-3-(dimethylamino)propan-1-one Chemical compound CN(C)CCC(=O)C1=CC(F)=CC=C1F NZQUUDNNULYMRT-UHFFFAOYSA-N 0.000 description 1
- XAEZJTIXITVCMV-UHFFFAOYSA-N 1-(3,5-difluorophenyl)-3-(dimethylamino)propan-1-one Chemical compound CN(C)CCC(=O)C1=CC(F)=CC(F)=C1 XAEZJTIXITVCMV-UHFFFAOYSA-N 0.000 description 1
- OXJLDNSPGPBDCP-UHFFFAOYSA-N 1-(3,5-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC(F)=C1 OXJLDNSPGPBDCP-UHFFFAOYSA-N 0.000 description 1
- LYUPJHVGLFETDG-UHFFFAOYSA-N 1-phenylbutan-2-ol Chemical compound CCC(O)CC1=CC=CC=C1 LYUPJHVGLFETDG-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DEGMFYNULJKSFA-UHFFFAOYSA-N 3-(3-fluorophenyl)propanoyl chloride Chemical compound FC1=CC=CC(CCC(Cl)=O)=C1 DEGMFYNULJKSFA-UHFFFAOYSA-N 0.000 description 1
- VGNRGOGIWXMVLI-UHFFFAOYSA-N 3-(4-chlorophenyl)propanoyl chloride Chemical compound ClC(=O)CCC1=CC=C(Cl)C=C1 VGNRGOGIWXMVLI-UHFFFAOYSA-N 0.000 description 1
- QXOVXYKNXDTLTR-UHFFFAOYSA-N 3-(4-methylphenyl)propanoyl chloride Chemical compound CC1=CC=C(CCC(Cl)=O)C=C1 QXOVXYKNXDTLTR-UHFFFAOYSA-N 0.000 description 1
- MYIFKPGNLNJEGE-UHFFFAOYSA-N 3-(dimethylamino)-1-(3-fluorophenyl)propan-1-one Chemical compound CN(C)CCC(=O)C1=CC=CC(F)=C1 MYIFKPGNLNJEGE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- MBVCESWADCIXJN-UHFFFAOYSA-N 5-Bromoisatin Chemical compound BrC1=CC=C2NC(=O)C(=O)C2=C1 MBVCESWADCIXJN-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000006153 Pfitzinger synthesis reaction Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- KVPNBBUKZBDNBJ-OIXVRUHCSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyrazine-2-carboxamide pyridine-4-carbohydrazide Chemical compound NC(=O)c1cnccn1.NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KVPNBBUKZBDNBJ-OIXVRUHCSA-N 0.000 description 1
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- CBPYOHALYYGNOE-UHFFFAOYSA-M potassium;3,5-dinitrobenzoate Chemical compound [K+].[O-]C(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 CBPYOHALYYGNOE-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39871102P | 2002-07-25 | 2002-07-25 | |
| PCT/EP2003/050322 WO2004011436A1 (en) | 2002-07-25 | 2003-07-18 | Quinoline derivatives and their use as mycobacterial inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ538391A true NZ538391A (en) | 2005-10-28 |
Family
ID=31188461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ538391A NZ538391A (en) | 2002-07-25 | 2003-07-18 | Quinoline derivatives and their use as mycobacterial inhibitors |
Country Status (37)
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902225B2 (en) * | 2004-01-23 | 2011-03-08 | Janssen Pharmaceutica Nv | Mycobacterial inhibitors |
| EA011359B1 (ru) | 2004-01-23 | 2009-02-27 | ŠÆŠ½ŃŃŠµŠ½ Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŠŗŠ° Š.Š. | ŠŠ°Š¼ŠµŃŠµŠ½Š½ŃŠµ Ń ŠøŠ½Š¾Š»ŠøŠ½Ń Šø ŠøŃ ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ Š² ŠŗŠ°ŃŠµŃŃŠ²Šµ Š¼ŠøŠŗŠ¾Š±Š°ŠŗŃŠµŃŠøŠ°Š»ŃŠ½ŃŃ ŠøŠ½Š³ŠøŠ±ŠøŃŠ¾ŃŠ¾Š² |
| EP1713776B1 (en) * | 2004-01-29 | 2008-05-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives for use as mycobacterial inhibitors |
| EA010651B1 (ru) * | 2004-05-28 | 2008-10-30 | ŠÆŠ½ŃŃŠµŠ½ Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŠŗŠ° Š.Š. | ŠŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ Š·Š°Š¼ŠµŃŠµŠ½Š½ŃŃ Ń ŠøŠ½Š¾Š»ŠøŠ½Š¾Š²ŃŃ ŠæŃŠ¾ŠøŠ·Š²Š¾Š“Š½ŃŃ Š“Š»Ń Š»ŠµŃŠµŠ½ŠøŃ Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹, Š²ŃŠ·ŃŠ²Š°ŠµŠ¼ŃŃ Š¼ŠøŠŗŠ¾Š±Š°ŠŗŃŠµŃŠøŃŠ¼Šø, ŃŠµŠ·ŠøŃŃŠµŠ½ŃŠ½ŃŠ¼Šø Šŗ Š»ŠµŠŗŠ°ŃŃŃŠ²ŠµŠ½Š½ŃŠ¼ ŃŃŠµŠ“ŃŃŠ²Š°Š¼ |
| PL1797115T3 (pl) * | 2004-09-28 | 2017-12-29 | Janssen Pharmaceutica N.V. | Domena wiÄ Å¼Ä ca bakteryjnej syntazy ATP |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | KinoliiniĀhendid kasutamiseks latentse tuberkuloosi ravis |
| BG66437B1 (bg) * | 2004-12-24 | 2014-07-31 | Janssen Pharmaceutica N.V. | ŠŠ·ŠæŠ¾Š»Š·Š²Š°Š½Šµ Š½Š° Ń ŠøŠ½Š¾Š»ŠøŠ½Š¾Š²Šø ŃŃŠµŠ“ŠøŠ½ŠµŠ½ŠøŃ Š·Š° Š»ŠµŃŠµŠ½ŠøŠµ Š½Š° Š»Š°ŃŠµŠ½ŃŠ½Š° ŃŃŠ±ŠµŃŠŗŃŠ»Š¾Š·Š° |
| NZ563819A (en) * | 2005-05-25 | 2011-01-28 | Janssen Pharmaceutica Nv | Process for preparing (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-napthalenyl-beta-phenyl-3-quinolineethanol (R207910) |
| EE05697B1 (et) * | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
| TWI380819B (zh) * | 2005-06-08 | 2013-01-01 | Janssen Pharmaceutica Nv | ēØä½ęē“°čåä¹å¹åč”ēē© |
| JP5349730B2 (ja) * | 2005-06-09 | 2013-11-20 | ćøć¤ć³ć»ć³ć»ćć¢ć¼ćć·ć¦ć¼ćć«ć»ćć¼ć ćć¼ć¼ć»ććØć³ćć¼ćć·ć¤ćć | ęććÆććŖć¢å¤ćØćć¦ć®ćććŖć³čŖå°ä½ |
| EA010601B1 (ru) * | 2005-06-09 | 2008-10-30 | ŠÆŠ½ŃŃŠµŠ½ Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŠŗŠ° Š.Š. | ŠŃŠ¾ŠøŠ·Š²Š¾Š“Š½ŃŠµ Ń ŠøŠ½Š¾Š»ŠøŠ½Š° Š² ŠŗŠ°ŃŠµŃŃŠ²Šµ Š°Š½ŃŠøŠ±Š°ŠŗŃŠµŃŠøŠ°Š»ŃŠ½ŃŃ Š°Š³ŠµŠ½ŃŠ¾Š² |
| KR101318181B1 (ko) * | 2005-06-09 | 2013-10-16 | ģģ¼ ķė§ģķ°ģ¹“ ģ.ėøģ“. | ķź· ģ ė”ģģ ķ“ėė¦° ģ ėģ²“ |
| JO3270B1 (ar) * | 2005-06-28 | 2018-09-16 | Janssen Pharmaceutica Nv | Ł Ų“ŲŖŁŲ§ŲŖ ŁŁŁŁŁŁŁŁ ŲØŲµŁŲ© Ų¹ŁŲ§Ł Ł Ł Ų¶Ų§ŲÆŲ© ŁŁŲØŁŲŖŁŲ±ŁŲ§ |
| DK1898909T3 (en) * | 2005-06-28 | 2017-02-06 | Janssen Pharmaceutica Nv | QUINOLIN DERIVATIVES AS ANTIBACTERIAL AGENTS |
| JO2752B1 (en) * | 2005-06-28 | 2014-03-15 | Ų“Ų±ŁŲ© Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł. ŁŁ | Quinoline derivatives acting as antibacterial agents |
| JO3077B1 (ar) * | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | Ł Ų“ŲŖŁŲ§ŲŖ ŁŁŁŁŁŁŁŁ Ł Ų¶Ų§ŲÆŲ© ŁŁŲØŁŲŖŁŲ±ŁŲ§ |
| JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł. ŁŁ | Quinoline derivatives acting as antibacterial agents |
| JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | Ų¬Ų§ŁŲ³Ł ŁŲ§Ų±Ł Ų³ŁŲŖŁŲ§ Ų§Ł ŁŁ | Quinoline derivatives acting as antibacterial agents |
| JO2855B1 (en) * | 2005-08-03 | 2015-03-15 | Ų“Ų±ŁŲ© Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł. ŁŁ | Quinoline derivatives acting as antibacterial agents |
| EP1917245A1 (de) | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Heterocyclische verbindungen und ihre verwendung als bindungspartner fĆ¼r 5-ht5-rezeptoren |
| DE102005044817A1 (de) | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | ŠÆŠ½ŃŃŠµŠ½ Š¤Š°ŃŠ¼Š°ŃŠµŠ²ŃŠøŠŗŠ° Š.Š. | Š¤ŃŠ¼Š°ŃŠ°ŃŠ½Š° ŃŃŠ»Ń (Š°Š»ŃŃŠ° s, Š±ŠµŃŠ° r)-6-Š±ŃŠ¾Š¼-Š°Š»ŃŃŠ°-[2-(Š“ŠøŠ¼ŠµŃŠøŠ»Š°Š¼ŃŠ½Š¾)ŠµŃŠøŠ»]-2-Š¼ŠµŃŠ¾ŠŗŃŃ-Š°Š»ŃŃŠ°-1-Š½Š°ŃŃŠ°Š»ŠµŠ½ŃŠ»-Š±ŠµŃŠ°-ŃŠµŠ½ŃŠ»-3-Ń ŃŠ½Š¾Š»ŃŠ½ŠµŃŠ°Š½Š¾Š»Ń |
| JO2685B1 (en) * | 2006-12-06 | 2013-03-03 | Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł ŁŁ | Quinoline antibacterial derivatives |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł. ŁŁ | Quinoline antibacterial derivatives |
| JO2684B1 (en) * | 2006-12-06 | 2013-03-03 | Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł ŁŁ | Quinoline antibacterial derivatives |
| JO2725B1 (en) * | 2006-12-06 | 2013-09-15 | Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł. ŁŁ | Quinoline antibacterial derivatives |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | Ł Ų“ŲŖŁŲ§ŲŖ Ų§ŁŁŁŁŁŁŁŁŁ Ų§ŁŁ Ų¶Ų§ŲÆŲ© ŁŁŲ¬Ų±Ų§Ų«ŁŁ |
| JO2970B1 (en) * | 2006-12-06 | 2016-03-15 | Ų¬Ų§ŁŲ³ŁŁ ŁŲ§Ų±Ł Ų§Ų³ŁŲŖŁŁŲ§ Ų§Ł. ŁŁ | Quinoline antibacterial derivatives |
| RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ŠŠŠ "Š¤Š°ŃŠ¼-Š”ŠøŠ½ŃŠµŠ·" | ŠŠ¾Š²ŃŠµ ŠæŃŠ¾ŠøŠ·Š²Š¾Š“Š½ŃŠµ Ń ŠøŠ½Š¾Š»ŠøŠ½Š°, ŃŠæŠ¾ŃŠ¾Š± ŠøŃ ŠæŠ¾Š»ŃŃŠµŠ½ŠøŃ, ŠøŃ ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ Š“Š»Ń Š»ŠµŃŠµŠ½ŠøŃ Š¼ŠøŠŗŠ¾Š±Š°ŠŗŃŠµŃŠøŠ°Š»ŃŠ½ŃŃ ŠøŠ½ŃŠµŠŗŃŠøŠ¹, ŃŠ°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠ°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŃ Š½Š° ŠøŃ Š¾ŃŠ½Š¾Š²Šµ |
| CN102249935B (zh) * | 2010-05-17 | 2015-05-20 | äøå½äŗŗę°č§£ę¾ååäŗå»å¦ē§å¦é¢ęÆē©čÆē©ē ē©¶ę | č³é¦2-äøéē±»ååē©åå ¶å»čÆēØé |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | ŠŠ°ŠŗŃŃŃŠ¾Šµ ŠŠŗŃŠøŠ¾Š½ŠµŃŠ½Š¾Šµ ŠŠ±ŃŠµŃŃŠ²Š¾ "Š¤Š°ŃŠ¼-Š”ŠøŠ½ŃŠµŠ·" | ŠŃŠ¾ŠøŠ·Š²Š¾Š“Š½ŃŠµ Ń ŠøŠ½Š¾Š»ŠøŠ½Š°, Š² ŃŠ°ŃŃŠ½Š¾ŃŃŠø 5,6,7-Š·Š°Š¼ŠµŃŠµŠ½Š½ŃŠµ 1-(2-Ń Š»Š¾ŃŃ ŠøŠ½Š¾Š»ŠøŠ½-3-ŠøŠ»)-4-Š“ŠøŠ¼ŠµŃŠøŠ»Š°Š¼ŠøŠ½Š¾-2-(Š½Š°ŃŃŠ°Š»ŠøŠ½-1-ŠøŠ»)-1-ŃŠµŠ½ŠøŠ»Š±ŃŃŠ°Š½-2-Š¾Š»Ń, ŃŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃŃŠµŠ½ŠøŃ Šø ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ ŃŠ¾ŠµŠ“ŠøŠ½ŠµŠ½ŠøŠ¹ |
| WO2013160431A1 (en) | 2012-04-27 | 2013-10-31 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| US9133167B2 (en) | 2012-04-27 | 2015-09-15 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| US9572809B2 (en) | 2012-07-18 | 2017-02-21 | Spero Trinem, Inc. | Combination therapy to treat Mycobacterium diseases |
| NZ708742A (en) | 2012-12-21 | 2020-06-26 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| RU2530493C1 (ru) * | 2013-04-22 | 2014-10-10 | ŠŠ°ŠŗŃŃŃŠ¾Šµ ŠŠŗŃŠøŠ¾Š½ŠµŃŠ½Š¾Šµ ŠŠ±ŃŠµŃŃŠ²Š¾ "Š¤Š°ŃŠ¼-Š”ŠøŠ½ŃŠµŠ·" | ŠŃŠ¾ŠøŠ·Š²Š¾Š“Š½ŃŠµ Ń ŠøŠ½Š¾Š»ŠøŠ½Š°, Š² ŃŠ°ŃŃŠ½Š¾ŃŃŠø 6,7-Š·Š°Š¼ŠµŃŠµŠ½Š½ŃŠµ 1-(2-Ń Š»Š¾ŃŃ ŠøŠ½Š¾Š»ŠøŠ½-3-ŠøŠ»)-4-Š“ŠøŠ¼ŠµŃŠøŠ»Š°Š¼ŠøŠ½Š¾-2-(Š½Š°ŃŃŠ°Š»ŠøŠ½-1-ŠøŠ»)-1-ŃŠµŠ½ŠøŠ»Š±ŃŃŠ°Š½-2-Š¾Š»Ń, ŃŠæŠ¾ŃŠ¾Š± ŠøŃ ŠæŠ¾Š»ŃŃŠµŠ½ŠøŃ Šø ŠæŃŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ ŃŠ¾ŠµŠ“ŠøŠ½ŠµŠ½ŠøŠ¹ Š“Š»Ń Š»ŠµŃŠµŠ½ŠøŃ ŠøŠ½ŃŠµŠŗŃŠøŠ¾Š½Š½ŃŃ Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹ Š¼ŠøŠŗŠ¾Š±Š°ŠŗŃŠµŃŠøŠ°Š»ŃŠ½Š¾Š¹ ŠæŃŠøŃŠ¾Š“Ń, Š² ŃŠ°ŃŃŠ½Š¾ŃŃŠø ŃŃŠ±ŠµŃŠŗŃŠ»ŠµŠ·Š° |
| CN105017147B (zh) * | 2014-04-30 | 2019-02-01 | äøå½å»å¦ē§å¦é¢čÆē©ē ē©¶ę | äøē§åę¶åå©ēØBedaquilineē«ä½åå¦å¼ęä½ēę¹ę³ |
| CN105085396B (zh) * | 2014-05-07 | 2017-08-08 | å½čÆéå¢å½ēčÆäøęéå ¬åø | ēØäŗå¶å¤č“č¾¾å¹åēäøé“ä½åå ¶å¶å¤ę¹ę³ååŗēØ |
| CN105085395B (zh) * | 2014-05-07 | 2017-09-26 | å½čÆéå¢å½ēčÆäøęéå ¬åø | č“č¾¾å¹åēå¶å¤ę¹ę³ |
| CN105198808B (zh) * | 2014-05-27 | 2017-08-25 | åäŗ¬äøēčÆäøęéč“£ä»»å ¬åø | äøē§é«ęēäŗ§č“č¾¾å¹åēę¹ę³ |
| CN105175329B (zh) * | 2014-06-10 | 2017-09-19 | éåŗå£åę¦čÆäøč”份ęéå ¬åø | äøē§č“č¾¾å¹åę¶ęä½ēåęč·Æēŗæåę¹ę³ |
| CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | äøęµ·åå¦å»čÆē§ęęéå ¬åø | å”å¶č”ēē©åå ¶ä½äøŗęåęÆęčēåŗēØ |
| CA2954872C (en) * | 2014-07-14 | 2019-08-13 | Cisen Pharmaceutical Co., Ltd. | Pyridine derivatives and anti-mycobacterial use thereof |
| CN105440051B (zh) * | 2014-09-19 | 2019-07-05 | éåŗå»čÆå·„äøē ē©¶é¢ęéč“£ä»»å ¬åø | äøē§ęē»ę øēå»å©å”å¶č”ēē© |
| CZ2014708A3 (cs) | 2014-10-16 | 2016-04-27 | Zentiva, K.S. | Soli Bedaquilinu |
| CZ201533A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | ZpÅÆsob izolace smÄsi enantiomerÅÆ |
| CZ201535A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | NovĆ© možnosti chirĆ”lnĆ resoluce bedaquilinu |
| CZ201534A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | NovĆ© možnosti chirĆ”lnĆ resoluce bedaquilinu |
| PL3250182T3 (pl) | 2015-01-27 | 2023-07-31 | Janssen Pharmaceutica Nv | Kompozycje dyspergowalne |
| AU2016255724B2 (en) * | 2015-04-29 | 2020-05-14 | The State of Israel, Ministry of Agriculture and Rural Development Agricultural Research Organization (ARO) (Volcani Center) | Anti-phytopathogenic compositions |
| CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | éåŗå£åę¦čÆäøč”份ęéå ¬åø | č“č¾¾å¹åę¶åćē»åē©åå ¶å¶å¤ę¹ę³ |
| CZ2015391A3 (cs) | 2015-06-09 | 2016-12-21 | Zentiva, K.S. | SÅÆl bedaquilinu s kyselinou citronovou |
| PL3316969T3 (pl) | 2015-07-02 | 2022-06-20 | Janssen Sciences Ireland Unlimited Company | ZwiÄ zki przeciwbakteryjne |
| CN105061387A (zh) * | 2015-07-17 | 2015-11-18 | čå·å¤§å¦ | äŗč³åŗéē±»ēØ ēÆē±»ååē©ćå¶å¤ę¹ę³åēØé |
| CN107848978B (zh) * | 2015-07-24 | 2021-04-02 | ęµę±ęµ·ę£čÆäøč”份ęéå ¬åø | äøē§åē¦»č“č¾¾å¹åéåƹę å¼ęä½aēę¹ę³ |
| RU2018111482A (ru) * | 2015-10-20 | 2019-11-21 | Š§Š¶ŃŃŠ·ŃŠ½ Š„ŠøŃŃŠ½Ń Š¤Š°ŃŠ¼Š°ŃŃŃŃŠøŠŗŠ°Š» ŠŠ¾., ŠŃŠ“. | ŠŃŠøŃŃŠ°Š»Š»ŠøŃŠµŃŠŗŠøŠµ ŃŠ¾ŃŠ¼Ń Š±ŠµŠ“Š°ŠŗŠ²ŠøŠ»ŠøŠ½ ŃŃŠ¼Š°ŃŠ°ŃŠ° Šø ŃŠæŠ¾ŃŠ¾Š±Ń ŠøŃ ŠæŠ¾Š»ŃŃŠµŠ½ŠøŃ |
| WO2017121323A1 (zh) * | 2016-01-13 | 2017-07-20 | č¾°ę¬£čÆäøč”份ęéå ¬åø | äøē§å”å¶č”ēē©ē±»ååē©ēå¶å¤ę¹ę³åå ¶äøé“ä½åę¶å |
| WO2017149551A1 (en) * | 2016-03-03 | 2017-09-08 | Council Of Scientific & Industrial Research | Substituted aurone alkaloids as anti-mycobacterial agents |
| EP3426255B1 (en) * | 2016-03-07 | 2022-11-30 | The Global Alliance for TB Drug Development, Inc. | Antibacterial compounds and uses thereof |
| CN109415349A (zh) | 2016-06-16 | 2019-03-01 | ē±å°å °č©¹ę£®ē§å¦å ¬åø | ęēÆååē©ä½äøŗęē»čå |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocĆclicos como antibacterianos |
| EP4417262A3 (en) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Combination therapy |
| EP4356968A3 (en) | 2017-07-14 | 2024-07-10 | JANSSEN Pharmaceutica NV | Long-acting formulations |
| CN109384716B (zh) * | 2017-08-11 | 2021-06-29 | ęµ·åčÆäøč”份ęéå ¬åø | äøē§ę°ä»£å¹åååē©åå ¶å¶å¤åēØé |
| US20220062319A1 (en) | 2019-01-09 | 2022-03-03 | Janssen Pharmaceutica Nv | Combination in the treatment of nontuberculous mycobacterial diseases |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburghāof the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| WO2020161743A1 (en) | 2019-02-08 | 2020-08-13 | Mylan Laboratories Limited | Process for the preparation of bedaquiline fumarate |
| ES2978573T3 (es) | 2019-09-13 | 2024-09-16 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos |
| CN112574175B (zh) * | 2019-09-29 | 2023-11-14 | åäŗ¬éæę¾³å»čÆē§ęęéå ¬åø | å¹åē±»ååē©ćå ¶å¶å¤ę¹ę³åēØé |
| KR20220071199A (ko) | 2019-09-30 | 2022-05-31 | ģģ¼ ģ¬ģ“ģøģģ¦ ģģ¼ėė ģøė¦¬ėÆøķ°ė ģ»“ķ¼ė | 4-ķ“ėė¦¬ė ¼ ķź· ķķ©ė¬¼ |
| KR20220075335A (ko) | 2019-09-30 | 2022-06-08 | ģģ¼ ģ¬ģ“ģøģģ¦ ģģ¼ėė ģøė¦¬ėÆøķ°ė ģ»“ķ¼ė | ķź· ķķ©ė¬¼ |
| CN110804016B (zh) * | 2019-12-05 | 2022-11-04 | ē¦å»ŗēå¾®ēē©ē ē©¶ę | ęē»ę øåęęčēäŗč³åŗå¹åč”ēē© |
| CA3162532A1 (en) | 2019-12-27 | 2021-07-01 | Augusto Eugenio Pardal Filipe | Antibacterial quinolines |
| KR102303635B1 (ko) | 2020-07-01 | 2021-09-17 | ėģģģ¤ķ° ģ£¼ģķģ¬ | (1r,2s)-1-(6-ėøė”ėŖØ-2-ė©ķ”ģķ“ėė¦°-3-ģ¼)-4-ėė©ķøģėÆøė ø-2-(1-ėķķø)-1-ķė-ė¶ķ-2-ģ¬ ė° ģ“ģ ģ½ģ ķģ ģ¼ė” ķģ© ź°ė„ķ ģ¼ģ ģ ģ”°ė°©ė² |
| CA3182854A1 (en) | 2020-07-09 | 2022-01-13 | Rene Holm | Long-acting formulations |
| MX2023000439A (es) | 2020-07-09 | 2023-02-09 | Janssen Pharmaceutica Nv | Formulaciones a largo plazo. |
| WO2022008644A1 (en) | 2020-07-09 | 2022-01-13 | Janssen Pharmaceutica Nv | Long-acting formulations |
| KR20230107275A (ko) | 2020-11-12 | 2023-07-14 | ģģ¼ ķė§ģķ°ģ¹“ ģ.ėøģ“. | ė¹ź²°ķµģ± ė§ģ“ģ½ė°ķ ė¦¬ģ ģ§ķģ ģ¹ė£ģģ ė² ė¤ķ¼ė¦°, ģķė¶ķØ ė° ė§ķ¬ė”¤ė¼ģ“ėģ ģ”°ķ©ė¬¼ |
| AU2022237769A1 (en) | 2021-03-16 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN117440958A (zh) | 2021-03-17 | 2024-01-23 | ē±å°å °č©¹ę£®ē§å¦å ¬åø | ęčååē© |
| MX2023010948A (es) | 2021-03-17 | 2023-11-28 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| MX2024000111A (es) | 2021-06-29 | 2024-01-19 | Tecnimede Sociedade Tecnico Medicinal Sa | Compuestos heterociclicos para el tratamiento de tuberculosis. |
| JP2024540052A (ja) | 2021-10-28 | 2024-10-31 | ć¤ć³ć»ć³ć»ćµć¤ćØć³ć·ćŗć»ć¢ć¤ć«ć©ć³ćć»ć¢ć³ćŖććććć»ć«ć³ććć¼ | ē“°čęęć®ę²»ēć«ä½æēØććććć®ć¤ććć¾ććŖćøć³ć¢ććåć³é¢é£ååē© |
| WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
| CN114835641B (zh) * | 2022-05-07 | 2024-03-15 | åäŗ¬ę°čæå»čÆē§ęęéå ¬åø | äøē§3-čåŗ-6-ęŗ“-2-ē²ę°§åŗå¹åēåęę¹ę³ |
| CN117050006A (zh) * | 2022-05-13 | 2023-11-14 | å¹æå·åč¶å»čÆē§ęęéå ¬åø | äøē§å”å¶č”ēē©ćäøé“ä½ćå¶å¤ę¹ę³ååŗēØ |
| WO2023232838A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bedaquiline for use in the treatment of leprosy |
| WO2024068699A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
| WO2024068693A1 (en) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Long-acting formulations |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN120225518A (zh) * | 2022-11-15 | 2025-06-27 | ä¼č±å©å©å ¬åø | AhręæåØå |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025068448A1 (en) | 2023-09-28 | 2025-04-03 | Janssen Pharmaceutica Nv | Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria |
| WO2025181475A1 (en) | 2024-02-27 | 2025-09-04 | The University Of Liverpool | Novel tuberculosis sterilization formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998018326A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| HUP0003364A3 (en) * | 1997-06-19 | 2002-03-28 | Sepracor Inc Marlborough | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| WO1999037365A1 (en) * | 1998-01-23 | 1999-07-29 | Fire Armour Pte Ltd. | Nozzle with axially and perpendicularly directed apertures |
| CA2318842A1 (en) * | 1998-01-26 | 1999-07-29 | Julie Dorothy Warrack | Quinoline derivatives as antibacterials |
| US6819431B2 (en) * | 2001-07-06 | 2004-11-16 | Zygo Corporation | Polymer retarder |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | KinoliiniĀhendid kasutamiseks latentse tuberkuloosi ravis |
| EE05697B1 (et) * | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
-
2003
- 2003-07-18 MX MXPA05001052A patent/MXPA05001052A/es active IP Right Grant
- 2003-07-18 AU AU2003262529A patent/AU2003262529B2/en not_active Expired
- 2003-07-18 HR HRP20050045AA patent/HRP20050045B1/hr not_active IP Right Cessation
- 2003-07-18 PT PT03771115T patent/PT1527050E/pt unknown
- 2003-07-18 PL PL375523A patent/PL222801B1/pl unknown
- 2003-07-18 ME MEP-2008-92A patent/ME00131B/me unknown
- 2003-07-18 BR BRPI0312927A patent/BRPI0312927B8/pt not_active IP Right Cessation
- 2003-07-18 DK DK10154018.5T patent/DK2301544T3/da active
- 2003-07-18 DE DE60332023T patent/DE60332023D1/de not_active Expired - Lifetime
- 2003-07-18 PT PT101540185T patent/PT2301544E/pt unknown
- 2003-07-18 JP JP2004523812A patent/JP4484703B2/ja not_active Expired - Lifetime
- 2003-07-18 KR KR1020057000447A patent/KR100733577B1/ko not_active Expired - Lifetime
- 2003-07-18 HR HRP20120190AA patent/HRP20120190B1/hr not_active IP Right Cessation
- 2003-07-18 NZ NZ538391A patent/NZ538391A/en not_active IP Right Cessation
- 2003-07-18 RS YU20050058A patent/RS52431B/sr unknown
- 2003-07-18 UA UAA200501778A patent/UA82198C2/uk unknown
- 2003-07-18 CN CNB038177137A patent/CN1325475C/zh not_active Expired - Lifetime
- 2003-07-18 ES ES10154018T patent/ES2395237T3/es not_active Expired - Lifetime
- 2003-07-18 SI SI200331819T patent/SI1527050T1/sl unknown
- 2003-07-18 SI SI200332211T patent/SI2301544T1/sl unknown
- 2003-07-18 EA EA200500257A patent/EA008937B1/ru active Protection Beyond IP Right Term
- 2003-07-18 EP EP10154018A patent/EP2301544B1/en not_active Expired - Lifetime
- 2003-07-18 DK DK03771115.7T patent/DK1527050T3/da active
- 2003-07-18 ES ES03771115T patent/ES2343458T3/es not_active Expired - Lifetime
- 2003-07-18 AT AT03771115T patent/ATE463482T1/de active
- 2003-07-18 CA CA2493225A patent/CA2493225C/en not_active Expired - Lifetime
- 2003-07-18 EP EP03771115A patent/EP1527050B1/en not_active Expired - Lifetime
- 2003-07-18 AP AP2005003210A patent/AP2421A/xx active
- 2003-07-18 WO PCT/EP2003/050322 patent/WO2004011436A1/en not_active Ceased
- 2003-07-18 CN CN2007101049477A patent/CN101070304B/zh not_active Expired - Lifetime
- 2003-07-24 AR AR20030102655A patent/AR040673A1/es active IP Right Grant
- 2003-07-24 TW TW092120160A patent/TWI323730B/zh active
- 2003-07-24 MY MYPI20032793A patent/MY143564A/en unknown
-
2004
- 2004-12-08 US US11/007,026 patent/US7498343B2/en active Active
- 2004-12-29 IS IS7620A patent/IS2914B/is unknown
-
2005
- 2005-01-24 IL IL166457A patent/IL166457A/en active IP Right Grant
- 2005-01-24 ZA ZA200500680A patent/ZA200500680B/xx unknown
- 2005-01-27 NO NO20050476A patent/NO329935B1/no not_active IP Right Cessation
-
2009
- 2009-12-10 IL IL202655A patent/IL202655A/en active IP Right Grant
-
2010
- 2010-07-07 CY CY20101100634T patent/CY1111882T1/el unknown
-
2012
- 2012-12-19 CY CY20121101241T patent/CY1113497T1/el unknown
-
2014
- 2014-08-14 NL NL300684C patent/NL300684I2/nl unknown
- 2014-08-14 LU LU92520C patent/LU92520I2/xx unknown
- 2014-08-14 CY CY2014033C patent/CY2014033I1/el unknown
- 2014-08-14 HU HUS1400047C patent/HUS1400047I1/hu unknown
- 2014-08-14 BE BE2014C051C patent/BE2014C051I2/nl unknown
- 2014-08-18 FR FR14C0060C patent/FR14C0060I2/fr active Active
- 2014-08-20 NO NO2014021C patent/NO2014021I1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2301544B1 (en) | Quinoline derivatives as intermediates to mycobacterial inhibitors | |
| CA2553269C (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
| AU2005210036B2 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
| HK1083496B (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| HK1113795B (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| MXPA06008315A (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| S38A | Application for proceedings under section 38 (amendment of specification with leave of commissioner) |
Free format text: BY WAY OF EXPLANATION |
|
| RENW | Renewal (renewal fees accepted) | ||
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| S883 | Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant) |
Free format text: THE INVENTORS (72) HAVE BEEN CORRECTED |
|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 JUL 2016 BY CPA GLOBAL Effective date: 20130607 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 18 JUL 2023 BY CPA GLOBAL Effective date: 20140903 |
|
| EXPY | Patent expired |